基础血浆B型脑钠肽水平对急性心力衰竭患者应用重组人脑利钠肽近期临床疗效的预测价值

doi:10.3969/j.issn.1002-1949.2019.06.010

Chinese Journal of Critical Care Medicine

2019, Vol. 39

Issue (6): 568-572 DOI: 10.3969/j.issn.1002-1949.2019.06.010

Predictive values of baseline plasma BNP levels for short-term clinical efficacy of acute heart failure patients with rhBNP treatment

Wu Zong-hu, Wang Shu-juan, Zhang Yan

Department of Cardiovascular Medicine, Zibo Central Hospital, Zibo 255000, China

Abstract
Figure/Table
References (15)
Related Citation (7)

Download: PDF (833 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore and analyze the predictive value of baseline plasma B-type natriuretic peptide (BNP) levels for short-term clinical efficacy of acute heart failure (AHF) patients with recombinant human brain natriuretic peptide (rhBNP) treatment. Methods From July 2015 to January 2018, 192 AHF patients treated with conventional therapies and rhBNP were retrospectively analyzed in our hospital. According to the short-time clinical effect of rhBNP, the patients were divided into the effective group and ineffective group. The baseline plasma BNP levels of all patients and rhBNP diuretic effect were analyzed and compared. Results There were 21 AHF patients (10.9%) with significantly effective treatment and 97 patients (50.5%) with generally effective treatment. The total efficacy rate was 61.5%. The patients were divided into the effective group (n=118) and ineffective group (n=74). The baseline plasma BNP levels of patients in ineffective group who had less diuretic effect was (1897.45±780.84) ng/L, significantly higher than that in effective group (P<0.05). After 24 h treatment of rhBNP, the efficacy of patients in the ineffective group was (408.75±315.47) mL, lower than that in effective group (P<0.05). The baseline plasma BNP levels were negatively correlated with the diuretic effect of rhBNP (r=-0.614,-0.530,-0.379, P<0.05). Conclusion The baseline plasma BNP levels could be the predictions of short-term clinical efficacy of acute heart failure patients treated with rhBNP, which is worthy of clinical attention.

Key words： B-type natriuretic peptide (BNP) Acute heart failure (AHF) Recombinant human brain natriuretic peptide (rhBNP) Clinical effect Diuretic effect

About author:: Wu Zong-hu, E-mail：stc917@126.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wu Zong-hu
	Wang Shu-juan
	Zhang Yan

Cite this article:

Wu Zong-hu,Wang Shu-juan,Zhang Yan. Predictive values of baseline plasma BNP levels for short-term clinical efficacy of acute heart failure patients with rhBNP treatment[J]. Chinese Journal of Critical Care Medicine, 2019, 39(6): 568-572.

URL:

http://www.cnemergency.org.cn/EN/10.3969/j.issn.1002-1949.2019.06.010 OR http://www.cnemergency.org.cn/EN/Y2019/V39/I6/568

［1］Teichman SL, Maisel AS, Storrow AB. Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs［J］. Crit Pathw Cardiol, 2015, 14(1): 12-24. ［2］Brunner-La Rocca HP, Bektas S. Biomarker guided therapy in chronic heart failure［J］. Card Fail Rev, 2015, 1(2): 96-101. ［3］孙勇, 操淮芳, 王刚, 等. 重组人脑钠肽与硝酸甘油对非ST段抬高ACS伴AHF患者心肌缺血及心功能水平的影响［J］. 中国循证心血管医学杂志, 2016, 8(10):1226-1229. ［4］Ural D, avuoglu Y, Eren M, et al. Diagnosis and management of acute heart failure［J］. Anatol J Cardiol, 2015, 15(11): 860-889. ［5］黄峻. 急性心力衰竭诊断和治疗指南［J］. 疑难病杂志, 2010, 9(7):557. ［6］McAteer A, Hravnak M, Chang Y, et al. The relationship between BNP, neurocardiac injury severity, noninvasive cardiac output, and outcomes after aneurysmal subarachnoid hemorrhage［J］. Biol Res Nurs, 2017, 19(5): 531-537. ［7］陈俊, 胡文彬, 谢辉. 血尿酸联合N-末端钠尿肽对老年急性心力衰竭患者近期不良预后的预测价值［J］. 心肺血管病杂志, 2018, 37(4): 316-319. ［8］Dai Y, Yang J, Takagi A, et al. In-hospital and long-term outcomes of congestive heart failure: Predictive value of B-type and amino-terminal pro-B-type natriuretic peptides and their ratio［J］. Exp Ther Med, 2017, 14(2): 1715-1721. ［9］杨黎明. 血浆脑钠肽水平与慢性心力衰竭患者预后的关系［J］. 中国循证心血管医学杂志, 2016, 8(9):1064-1065. ［10］吴小滢, 周玉杰，赵迎新, 等. 重组人脑利钠肽治疗急性心力衰竭患者的临床观察［J］. 心肺血管病杂志, 2011, 30(1):31-34. ［11］邹子扬, 陈金良, 孔令恩, 等. 新活素两种不同给药方法治疗急性左心衰竭的短期疗效前瞻性研究［J］. 中国循证心血管医学杂志, 2017, 9(5):584-587. ［12］Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)［J］. Eur Heart J, 2016, 37(29): 2315-2381. ［13］Aspromonte N, Gulizia MM, Clerico A, et al. ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure［J］. Eur Heart J Suppl, 2017, 19(Suppl D): D102-D112. ［14］Bettencourt PM. Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives［J］. Heart, 2005, 91(11): 1489-1494. ［15］Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials［J］. PLoS One, 2013, 8(3): e58 287.